IMUX:NASDAQ, Immunic, Inc.

IMUX stock overview

Immunic, Inc. (IMUX:NASDAQ) closed at $7.40 on October 27, 2026, up 1.65% on the day. The stock trades 57.5% below its 52-week high of $17.43 and 46.2% above its 52-week low of $5.06. Immunic, Inc. is part of the Health Care sector (Major Pharmaceuticals).

Key figures

Price: $7.40
Day change: +1.65%
Volume: 44,580
Average volume: 326,815
Market cap: 100M+
52-week range: $5.06 – $17.43
50-day average: $10.94
200-day average: $11.48

Price action over the past year

In 252 trading sessions since October 24, 2025, IMUX closed higher on 120 days (48%). Its best day was November 3, 2025 (+860.21%) and its worst was March 13, 2026 (-14.60%). The stock moved 10% or more in a single session 18 times. It opened at least 5% above the previous day's high 3 times.

Recent signals

Oct 26, 2026: Down 43.3% over 90 days, from $13.05 (Dips & Crashes scanner)
Oct 26, 2026: Trading sideways between $6.66 and $7.48 over 14 days (Sideways scanner)
Oct 21, 2026: News catalyst: Biotech (News Catalysts scanner)

IMUX news

Oct 22, 2026: New Strong Buy Stocks for October 22nd
Oct 21, 2026: Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Oct 19, 2026: Immunic to showcase phase 2 long-term MS disability data at MSToronto2026
Oct 19, 2026: Immunic adds new Chief People Officer ahead of Phase 3 readout
Oct 19, 2026: Immunic Appoints Jaa Roberson as Chief People Officer
Oct 7, 2026: Immunic to present four vidofludimus calcium abstracts at MSToronto2026
Oct 7, 2026: Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Sep 2, 2026: Immunic to host virtual relapsing MS R&D Day on September 9

About Immunic, Inc.

Vital Therapies Inc is a biotherapeutic company. It is involved in the business of developing liver treatment to improve survival in patients with Liver failure by providing hepatic support continuously for up to five days. The firm's main product candidate is ELAD system. It also owns VTL C3A cell bank which supports ELAD system.

Similar stocks

Find more stocks like IMUX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.